Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000390778

Medchemexpress LLC Butanedioic acid, 2-hydroxy-, (2S)-, compd. with (3S)-1-azabicyclo[2.2.2]oct-3-yl N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]carbamate (1:1) | 1629063-78-0 | 98.65% | 523.57 | 2 MG
SDP

Catalog No. 5000390778
Encompass_Preferred

Ibiglustat (L-Malic acid) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. It can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease. It can prevent additional GL-3 accumulation and could ameliorate the abundant levels of sphingolipid in FD cardiomyocytes.

  • Orally active
  • Brain-penetrant
  • Glucosylceramide synthase (GCS) inhibitor
  • Soluble in DMSO (≥ 100 mg/mL, 191.00 mM)
  • Can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease

Catalog No. 50-003-90778 Supplier Medchemexpress LLC Supplier No. HY16743A2MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Ibiglustat (L-Malic acid) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. It can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease. It can prevent additional GL-3 accumulation and could ameliorate the abundant levels of sphingolipid in FD cardiomyocytes.

  • Orally active
  • Brain-penetrant
  • Glucosylceramide synthase (GCS) inhibitor
  • Soluble in DMSO (≥ 100 mg/mL, 191.00 mM)
  • Can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.